Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.

Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, Popp H, Haferlach T, Erben P, Mix J, Müller MC, Beneke H, Müller L, Del Valle F, Aulitzky WE, Wittkowsky G, Schmitz N, Schulte C, Müller-Hermelink K, Hodges E, Whittaker SJ, Diecker F, Döhner H, Schuld P, Hehlmann R, Hochhaus A, Cross NC, Reiter A.

Leukemia. 2007 Jun;21(6):1183-8.

PMID:
17377585
2.

Complete response of myeloid sarcoma with FIP1L1-PDGFRA -associated myeloproliferative neoplasms to imatinib mesylate monotherapy.

Tang TC, Chang H, Chuang WY.

Acta Haematol. 2012;128(2):83-7. doi: 10.1159/000338217.

PMID:
22722648
3.

Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.

Barraco D, Carobolante F, Candoni A, Simeone E, Piccaluga P, Tabanelli V, Fanin R.

Eur J Haematol. 2014 Jun;92(6):541-5. doi: 10.1111/ejh.12272.

PMID:
24460680
4.

Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.

Rathe M, Kristensen TK, Møller MB, Carlsen NL.

Pediatr Blood Cancer. 2010 Oct;55(4):730-2. doi: 10.1002/pbc.22655.

PMID:
20589620
5.

FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.

Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA, Camoriano JK, Butterfield JH, Dewald GW, Tefferi A.

Leuk Res. 2006 Aug;30(8):965-70.

PMID:
16406016
6.

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.

Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG, Dewald GW, Tefferi A.

Blood. 2003 Nov 1;102(9):3093-6.

7.

FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.

Wang LN, Pan Q, Fu JF, Shi JY, Jin J, Li JM, Hu J, Zhao WL, Chen Z, Chen SJ.

Chin Med J (Engl). 2008 May 20;121(10):867-73.

PMID:
18706197
8.

Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia.

Shah S, Loghavi S, Garcia-Manero G, Khoury JD.

J Hematol Oncol. 2014 Mar 27;7:26. doi: 10.1186/1756-8722-7-26.

9.

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.

Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, Ho CL, Li CY, Dewald GW, Tefferi A.

Blood. 2004 Nov 15;104(10):3038-45.

10.

Case of polycythemia vera concurrent with FIP1L1-PDGFRA-positive myeloproliferative neoplasm with eosinophilia.

Alrwas A, Quesada JR, Marcos LA, Mehta SS, Shattuck BL, Nguyen ND, Juneja HS.

Cancer Genet. 2012 Oct;205(10):519-22. doi: 10.1016/j.cancergen.2012.05.010.

PMID:
22944561
11.

A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.

Helbig G, Stella-Hołowiecka B, Majewski M, Całbecka M, Gajkowska J, Klimkiewicz R, Moskwa A, Grzegorczyk J, Lewandowska M, Hołowiecki J.

Br J Haematol. 2008 Apr;141(2):200-4. doi: 10.1111/j.1365-2141.2008.07033.x.

PMID:
18307562
12.

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, Erben P, Popp H, Walz C, Hochhaus A, Roche-Lestienne C, Preudhomme C, Solomon E, Apperley J, Rondoni M, Ottaviani E, Martinelli G, Brito-Babapulle F, Saglio G, Hehlmann R, Cross NC, Reiter A, Grimwade D.

Blood. 2007 Jun 1;109(11):4635-40.

15.

Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.

Klion AD, Robyn J, Maric I, Fu W, Schmid L, Lemery S, Noel P, Law MA, Hartsell M, Talar-Williams C, Fay MP, Dunbar CE, Nutman TB.

Blood. 2007 Nov 15;110(10):3552-6.

16.

Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation.

Pardanani A, Lasho T, Barraco D, Patnaik M, Elala Y, Tefferi A.

Am J Hematol. 2016 Mar;91(3):E10-1. doi: 10.1002/ajh.24273. No abstract available.

PMID:
26663400
17.

A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease.

Chen D, Bachanova V, Ketterling RP, Begna KH, Hanson CA, Viswanatha DS.

Am J Surg Pathol. 2013 Jan;37(1):147-51. doi: 10.1097/PAS.0b013e31826df00b.

PMID:
23232855
18.

[The efficacy of imatinib mesylate for patients with myeloproliferative neoplasm (MPN) with eosinophilia].

Zhang Y, Qin TJ, Zhou CL, Liu L, Xiao ZJ.

Zhonghua Xue Ye Xue Za Zhi. 2009 Jun;30(6):381-4. Chinese.

PMID:
19951530
20.

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM.

N Engl J Med. 2002 Aug 15;347(7):481-7.

Items per page

Supplemental Content

Support Center